Our overall objective is to better understand the genetic and
environmental determinants of bladder cancer in humans. Specifically, we
aim (1) to determine whether genetic factors may alter risk of bladder
cancer associated with cigarette smoking. We will focus on the possible
roles of several genetically regulated enzymes involved in the activation
or inactivation of carcinogens present in cigarette smoke, including N-
acetyltransferase, cytochrome P4501A2 (CYP1A2), and glutathione S-
transferase M1 (GSTM1). We will determine if the slow acetylation and
rapid oxidation phenotypes, and the homozygous null GSTM1 genotype are
risk factors for bladder cancer in high- (Los Angeles whites) and low-
(Chinese) risk populations; (2) to assess other recently suggested or
inadequately studied risk or protective factors for bladder cancer,
including (a) passive smoke exposure, (b) vitamin A/carotenoid intake,
(c) vitamin C intake, (d) frequency of micturition, (e) long-term use of
analgesics, and (f) use of hair dyes; (3) to further understand the
relationship between smoking behavior and risk of bladder cancer in
populations at varying risk of bladder cancer. As an objective assessment
of biologically effective aromatic amine exposure from cigarettes or
other sources, we will assess levels of 3- and 4-aminobiphenyl (ABP)
hemoglobin adducts in all cases and controls. We will also measure levels
of urinary cotinine in all study subjects; and (4) to compare risk
factors in high versus low risk populations and to assess the impact of
comparable levels of exposure to these risk factors on level of risk in
these populations. A case-control study of bladder cancer involving
several biomarker measurements is proposed. Cases will be histologically
confirmed incident cases of bladder cancer among Los Angeles
whites/blacks and Shanghai Chinese aged 25-64 years. Controls will be
selected from the neighborhoods where the cases are living at the time
of cancer diagnosis. Each control will be individually matched to the
index case on race, sex, and date of birth (within 5 years). About 800
cases and 800 controls will be recruited in Los Angeles (blood and urine
specimens will be available on about 550 cases and 550 controls). In
Shanghai, we will complete interviews on about 560 cases and 560
controls, and collect blood and urine specimens from about 550 cases and
550 controls.
Error Notice
The database may currently be offline for maintenance and should be operational soon. If not, we have been notified of this error and will be reviewing it shortly.
We apologize for the inconvenience.
- The DCCPS Team.